Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Seltorexant with Rifampin in Healthy Subjects
NCT02661893Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2016
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of seltorexant in major depressive disorder (MDD) and Insomnia, sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Plasma Concentration at Day 12 and Area Under the Plasma Concentration-Time Curve at Day 12. Started Jan 2016; status: completed.
02
Drugs
seltorexant
03
Conditions
major depressive disorder (MDD)Insomnia
Beyond the preview
Go deeper on NCT02661893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02661893.